Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: A combined in vivo electrophysiological and microdialysis study

Neuroscience

Volumn 91, Issue 2, 1999, Pages 587-597

  Di Giovanni, G ^a   De Deurwaerdere P ^b   Di Mascio, M ^a   Di Matteo, V ^a   Esposito, E ^a   Spampinato, U ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Lab Neuropsychobiologie D   (France)

Author keywords

Dopamine neurons; Dopamine release; Electrophysiology; Microdialysis; Serotonin antagonists

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 [[2 (DIMETHYLAMINO)ETHYL]THIO] 3 PHENYLQUINOLINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; EPLIVANSERIN; RITANSERIN;

ANIMAL EXPERIMENT; ARTICLE; BRAIN ELECTROPHYSIOLOGY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMBIC CORTEX; MALE; MICRODIALYSIS; NEUROCHEMISTRY; NEUROPSYCHIATRY; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; ELECTROPHYSIOLOGY; EVOKED POTENTIALS; FLUOROBENZENES; INDOLES; LIMBIC SYSTEM; MALE; MICRODIALYSIS; NEURONS; NUCLEUS ACCUMBENS; PHENOLS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RITANSERIN; SEROTONIN ANTAGONISTS; TEGMENTUM MESENCEPHALI;

EID: 0032940954     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00655-1     Document Type: Article

References (66)

1. 2C receptor protein in human and rat brain using specific antisera. Neuropharmacology. 34:1995;1635-1645.
2. Andersson J.L., Nomikos G.G., Marcus M., Hertel P., Mathé J.M., Svensson T.H. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn-Schmiedeberg's Arch. Pharmac. 352:1995;374-385.
3. 2A antagonist MDL 100907 on midbrain dopamine (DA) neurons in rats: an electrophysiological study. Soc. Neurosci. Abstr. 22:1996;1323.
4. Azmitia E.C., Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. comp. Neurol. 179:1978;641-668.
5. 2 receptor subtypes: a family re-united? Trends pharmac. Sci. 16:1995;105-110.
6. Bean A.J., Roth R.H. Extracellular dopamine and neurotensin in rat prefrontal cortex in vivo: effects of median forebrain bundle stimulation frequency, stimulation pattern, and dopamine autoreceptors. J. Neurosci. 11:1991;2694-2702.
7. 2C receptors. Br. J. Pharmac. 115:1995;622-628.
8. 4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: a microdialysis study in the halothane-anesthetized rats. Neuropharmacology. 34:1995;269-279.
9. Bunney B.S., Walters J.R., Roth R.H., Aghajanian G.K. Dopaminergic neurons: effects of antipsychotic drugs and amphetamine on single cell activity. J. Pharmac. exp. Ther. 185:1973;560-571.
10. Cervo L., Grignaschi G., Samanin R. The role of the mesolimbic dopaminergic system in the desipramine effect in the forced swimming test. Eur. J. Pharmac. 178:1990;129-133.
11. Cervo L., Samanin R. Evidence that dopamine mechanisms in the nucleus accumbens are selectively involved in the effect of desipramine in the forced swimming test. Neuropharmacology. 26:1987;1469-1472.
12. Cervo L., Samanin R. Repeated treatment with imipramine and amitriptyline reduced the immobility of rats in the forced swimming test by enhancing dopamine mechanisms in the nucleus accumbens. J. Pharm. Pharmac. 40:1988;155-156.
13. Deutch A., Moghaddam B., Innis R., Krystal J.H., Aghajanian G.K., Bunney B.S., Charney D.S. Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophrenia Res. 4:1991;121-156.
14. 2 receptor antagonist, ritanserin. J. Neurochem. 59:1992;1459-1466.
15. Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.-S., King P., Pappas N., Brodie J D., Ashby C.R. Jr. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J. Neurosci. 15:1995;821-829.
16. Dray A., Gonye T.J., Oakley N.R., Tanner T. Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res. 113:1976;45-57.
17. 2B receptor protein in the rat. Br. J. Pharmac. 115:1995;105P.
18. 2C receptor messenger RNA in the basal ganglia of adult rats. J. comp. Neurol. 384:1997;233-247.
19. 2B receptor mRNA in the rat brain. Br. J. Pharmac. 114:1995;369P.
20. Fox S., Brotchie J. Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat. Eur. J. Pharmac. 301:1996;27-30.
21. Glennon R.A. Central serotonin receptors as targets for drug research. J. med. Chem. 30:1987;1-12.
22. 2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J. Pharmac. exp. Ther. 249:1989;673-680.
23. Gonon F.G. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience. 24:1988;19-28.
24. Grace A.A., Bunney B.S. Nigral dopamine neurons: intracellular recording and identification with L-DOPA injection and histofluorescence. Science. 210:1980;654-656.
25. Grace A.A., Bunney B.S. The control of firing pattern in nigral dopamine neurons: burst firing. J. Neurosci. 4:1984;2877-2890.
26. Hervé D., Pickel V.M., Tong H.J., Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res. 435:1987;71-83.
27. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P.A. VIIth International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmac. Rev. 46:1994;157-203.
28. Ichikawa J., Meltzer H.Y. Amperozide, a novel antipsychotic drug, inhibits the ability of D-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. J. Neurochem. 58:1992;2285-2291.
29. 1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur. J. Pharmac. 231:1993;223-229.
30. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiat. 153:1996;466-476.
31. 2B receptor antagonist with anxiolytic-like properties. Br. J. Pharmac. 117:1996;427-434.
32. 2C receptor antagonist. Neuropharmacology. 36:1997;609-620.
33. 2C receptors inhibit the activity of mesocortical and mesolimbic dopaminergic pathways: a combined dialysis and electrophysiological analysis. Soc. Neurosci. Abstr. 23:1997;975.
34. 2 antagonist. Molec. Pharmac. 27:1985;600-611.
35. 2 receptors. Psychopharmacology. 112:1993;S40-S54.
36. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology. 131:1997;57-63.
37. 2A receptor antagonist MDL 100,907 in a mouse model of schizophrenia is counteracted by ritanserin. J. neural Transm. 104:1997;561-564.
38. Meltzer H.Y., Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmac. Rev. 43:1991;587-604.
39. Mengod G., Nguyen H., Le H., Waeber C., Lübbert H., Palacios J.M. The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. Neuroscience. 15:1990;577-591.
40. Merlo Pich E., Samanin R. Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology. 89:1986;125-130.
41. Molineaux S.M., Jessell T.M., Axel R., Julius D. 5-HT1C receptor is a prominent serotonin receptor subtype in the central nervous system. Proc. natn. Acad. Sci. U.S.A. 86:1989;6793-6797.
42. Mori S., Matsuura T., Takino T., Sano Y. Light and electron microscopic immunohistochemical studies of serotonin nerve fibers in the substantia nigra of the rat, cat and monkey. Anat. Embryol. 176:1987;13-18.
43. Moukhles H., Bosler O., Bolam J.P., Vallée A., Umbriaco D., Geffard M., Doucet G. Quantitative and morphometric data indicate precise cellular interactions between serotonin and postsynaptic targets in rat substantia nigra. Neuroscience. 76:1997;1159-1171.
44. Nash J.F. Ketanserin pretreatment attenuates NDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci. 47:1990;2401-2408.
45. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic, New York.
46. Pazos A., Cortés R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res. 346:1985;231-249.
47. Phillipson O.T. Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat. J. comp. Neurol. 187:1979;117-144.
48. 2C receptors. Molec. Brain Res. 23:1994;163-178.
49. Prisco S., Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br. J. Pharmac. 116:1995;1923-1931.
50. Prisco S., Pagannone S., Esposito E. Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. J. Pharmac. exp. Ther. 271:1994;83-90.
51. 2C receptors. Neuroscience. 69:1995;903-913.
52. 2 receptor antagonist. J. Pharmac. exp. Ther. 262:1992;759-768.
53. 2A receptor blockade. J. Pharmac. exp. Ther. 277:1996;1541-1549.
54. 2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur. J. Pharmac. 223:1992;65-74.
55. 2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem. 62:1994;1382-1389.
56. 1A agonists. J. Pharmac. exp. Ther. 273:1995;101-112.
57. 2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons. J. Pharmac. exp. Ther. 274:1995;735-740.
58. 2 receptor antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis. J. Pharmac. exp. Ther. 260:1992;872-878.
59. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmac. exp. Ther. 266:1993;684-691.
60. Steinbusch H. W. M. (1984) Serotonin-immunoreactive neurons and their projections in the CNS. In Handbook of Chemical Neuroanatomy, Classical Transmitters and Transmitter Receptors in the CNS, Part II (eds Björklund A., Hökfelt T. and Kuhar M. J.), Vol. 3, pp. 68-125. Elsevier, Amsterdam.
61. Trent F., Tepper J.M. Dorsal raphé stimulation modifies striatal-evoked antidromic invasion of nigral dopaminergic neurons in vivo. Expl Brain Res. 84:1991;620-630.
62. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology. 98:1989;45-50.
63. Van Wijngaarden I., Tulp M. Th. M., Soudijn W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmac. 188:1990;301-312.
64. Wang R.Y. Dopaminergic neurons in the rat ventral tegmental area. I. Identification and characterization. Brain Res. Rev. 3:1981;123-140.
65. 6 with neuropeptides in rat striatum. J. comp. Neurol. 370:1996;405-414.
66. White F.J. Synaptic regulation of mesocorticolimbic dopamine neurons. A. Rev. Neurosci. 19:1996;405-436.